Open in Screener

IMVT

Immunovant Inc

Apr 02 • 04:00PM ET

24.50

-0.60 -2.39 %

Healthcare • Biotechnology • USA • NASD

Apr 02, 5:05 AMImmunovant's Phase 3 batoclimab thyroid eye disease trials miss primary endpoint, safety consistent with prior studies

Peers: MRNA REGN VRTX BMRN CRSP SRPT NTLA RARE EDIT ARCT

| Held by: XBI VTI VB IWM VXF VBR IWO IBB VBK VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.68	Insider Own	58.71%	Shs Outstand	203.32M	Perf Week	-3.39%
Market Cap	4.99B	Forward P/E	-	EPS next Y	-2.58	Insider Trans	16.10%	Shs Float	84.04M	Perf Month	-9.53%
Enterprise Value	3.99B	PEG	-	EPS next Q	-0.60	Inst Own	52.60%	Short Float	19.71%	Perf Quarter	-3.62%
Income	-464.20M	P/S	-	EPS this Y	4.03%	Inst Trans	5.74%	Short Ratio	11.96	Perf Half Y	49.94%
Sales	0.00M	P/B	5.05	EPS next Y	1.59%	ROA	-63.01%	Short Interest	16.57M	Perf YTD	-3.62%
Book/sh	4.85	P/C	5.01	EPS next 5Y	2.35%	ROE	-69.35%	52W High	29.25 -16.24%	Perf Year	49.21%
Cash/sh	4.89	P/FCF	-	EPS past 3/5Y	-24.09% -12.18%	ROIC	-47.07%	52W Low	12.72 92.61%	Perf 3Y	57.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.84% 5.07%	Perf 5Y	45.40%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2.53%	Oper. Margin	-	ATR (14)	1.33	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.74	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.76	Recom	1.56
Dividend Gr. 3/5Y	- -	Current Ratio	15.74	EPS Q/Q	19.41%	SMA20	-0.89%	Beta	0.70	Target Price	40.59
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-4.98%	Rel Volume	1.45	Prev Close	25.10
Employees	362	LT Debt/Eq	0.00	Earnings	Feb 06 BMO	SMA200	15.71%	Avg Volume	1.39M	Price	24.50
IPO	Jun 21, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.49% -	Trades		Volume	2,013,020	Change	-2.39%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-26	Initiated	Bernstein	Mkt Perform	$28
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$50
Oct-14-25	Initiated	Truist	Hold	$16
Jul-10-25	Resumed	Goldman	Neutral	$18
Mar-03-25	Initiated	Jefferies	Hold	$20
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform	$36
Oct-09-24	Reiterated	Oppenheimer	Outperform	$47 → $53
Mar-28-24	Initiated	Oppenheimer	Outperform	$50
Mar-13-24	Initiated	Goldman	Buy	$50
Feb-20-24	Initiated	JP Morgan	Overweight	$51
Feb-15-24	Initiated	Wolfe Research	Outperform	$55
Dec-12-23	Initiated	Deutsche Bank	Buy	$50
Oct-13-23	Upgrade	UBS	Neutral → Buy	$18 → $55
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$40
May-01-23	Initiated	BofA Securities	Buy	$26
Apr-25-23	Initiated	Citigroup	Buy	$28
Mar-31-23	Initiated	Piper Sandler	Overweight	$28
Mar-30-23	Initiated	Stifel	Buy	$28
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight	$30

Show Previous Ratings

Apr-02-26 08:20AM	Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM (BioPharma Dive)
07:00AM	Immunovant shares plunge after phase 3 trials fails to meet primary endpoint (Investing.com)
05:00AM	Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) (GlobeNewswire)
Mar-05-26 12:37PM	Immunovant Stock Surges 17% in 3 Months: What's Driving It? (Zacks)
Mar-04-26 02:30AM	Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update (Insider Monkey)
09:45AM	Loading…
Feb-19-26 09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-06-26 10:10AM	Immunovant Q3 Earnings Call Highlights (MarketBeat) +12.43%
07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
Feb-02-26 09:55AM	Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know (Zacks)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-23-26 05:25PM	Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-15-26 09:55AM	How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% (Zacks)
10:11AM	Loading…
Jan-12-26 10:11AM	Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling (Insider Monkey)
Dec-17-25 09:45AM	Share Offerings Prompt Huge Insider Buying in These 3 Biotechs (24/7 Wall St.)
Dec-15-25 04:28PM	Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse (Investor's Business Daily)
Dec-11-25 01:29AM	Immunovant Announces Pricing of $550 Million Common Stock Financing (GlobeNewswire) +5.31%
Dec-10-25 11:30AM	Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Nov-29-25 01:29PM	Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings (Insider Monkey)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
Nov-10-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 (GlobeNewswire)
Oct-31-25 10:03AM	Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results (Insider Monkey)
Oct-27-25 04:10PM	Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire) +13.15%
Oct-08-25 12:57AM	JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 (Insider Monkey)
Sep-30-25 04:00AM	Where is Immunovant (IMVT) Heading According to Analysts? (Insider Monkey)
Sep-10-25 11:30AM	Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-04-25 11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 06:17PM	Why Immunovant Stock Blasted Higher Today (Motley Fool) +10.82%
12:57PM	Loading…
12:57PM	Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-12-25 10:26AM	Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-11-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 (GlobeNewswire)
Jul-16-25 12:00PM	All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy (Zacks)
09:55AM	Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High? (Zacks)
09:38AM	Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating (Insider Monkey)
Jul-06-25 04:15AM	LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT (Insider Monkey)
Jun-02-25 12:00PM	Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-30-25 08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 (GlobeNewswire) +5.60%
May-09-25 09:02AM	Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? (Insider Monkey)
Apr-22-25 06:00AM	Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax (BioPharma Dive)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-08-25 10:05AM	Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? (Insider Monkey) -7.51%
Mar-24-25 01:56PM	Argenx: The Magic May Be Already Priced In (SeekingAlpha)
Mar-21-25 12:17PM	Immunovant price target raised to $61 from $58 at Stifel (TipRanks)
Mar-20-25 12:30PM	Immunovants batoclimab shows impressive efficacy in MG, says H.C. Wainwright (TipRanks)
10:19AM	IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success (Zacks)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
01:12PM	Immunovant will not seek approval for MG therapy, despite hitting endpoints (Clinical Trials Arena)
12:39PM	Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data (Benzinga)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Immunovant claims study success for immune disease drug but holds off on submission (BioPharma Dive)
07:45AM	Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire) -6.14%
Mar-05-25 07:13PM	Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +5.03%
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Feb-23-25 01:33PM	Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-22-25 12:53AM	Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? (Insider Monkey)
Feb-19-25 04:49PM	Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently (Insider Monkey)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
09:35AM	Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-10-25 11:57PM	Q3 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Feb-06-25 06:30AM	Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 (GlobeNewswire) -9.55%
Jan-30-25 05:03PM	Heres Why Immunovant, Inc. (IMVT) Will Double in 2025 (Insider Monkey)
Jan-17-25 11:10AM	Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-16-25 08:45AM	Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each (GuruFocus.com)
Jan-13-25 08:00AM	Immunovant Announces $450 Million Private Placement (GlobeNewswire)
Dec-20-24 07:20AM	Immunovant price target lowered to $45 from $47 at Wells Fargo (TipRanks)
Nov-21-24 05:31PM	Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-13-24 03:05AM	Q2 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 06:30AM	Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-29-24 06:30AM	Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting (GlobeNewswire)
Oct-01-24 09:58AM	Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip? (Insider Monkey)
Sep-30-24 11:12AM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy? (Insider Monkey)
Sep-09-24 12:54PM	What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? (Benzinga) -7.61%
09:13AM	Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses (Pharmaceutical Technology)
07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
03:55AM	Immunovant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-05-24 11:31AM	Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report? (Zacks) +9.55%
06:30AM	Immunovant to Host Graves' Disease Program Update on September 9, 2024 (GlobeNewswire)
Aug-09-24 12:20AM	Q1 2025 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 04:05PM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 (GlobeNewswire)
Jun-28-24 11:30AM	Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
02:26AM	Q4 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
May-30-24 04:02PM	After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay (Investor's Business Daily) -10.69%
11:29AM	Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus (Zacks)
07:22AM	Immunovant changes up plans for closely watched autoimmune drugs (BioPharma Dive)
05:53AM	Immunovant shunts next-gen FcRn drug ahead of batoclimab in race to rival Vyvgart (FierceBiotech.com)
May-29-24 09:53PM	IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024 (InvestorPlace)
04:06PM	Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
04:01PM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 (GlobeNewswire)
10:17AM	Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	Chief Executive Officer	Apr 01 '26	Option Exercise	14.46	368,750	5,332,125	368,750	Apr 03 04:33 PM
Venker Eric	Chief Executive Officer	Apr 02 '26	Sale	24.10	14,229	342,854	19,561	Apr 03 04:33 PM
Van Tuyl Christopher	Chief Legal Officer	Mar 18 '26	Sale	24.97	2,877	71,839	147,053	Mar 20 04:11 PM
Gloria Melanie	Chief Operating Officer	Feb 25 '26	Sale	27.85	3,238	90,184	170,273	Feb 27 04:07 PM
MICHAEL GEFFNER	Officer	Feb 10 '26	Proposed Sale	26.77	5,800	155,237		Feb 10 05:16 PM
Stout Jay S	Chief Technology Officer	Jan 21 '26	Sale	26.03	1,977	51,461	197,634	Jan 23 04:21 PM
Stout Jay S	Chief Technology Officer	Jan 07 '26	Sale	26.53	1,203	31,914	199,611	Jan 09 04:03 PM
Van Tuyl Christopher	Chief Legal Officer	Dec 18 '25	Sale	26.91	10,813	290,943	149,930	Dec 19 04:05 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Fromkin Andrew J.	Director	Dec 01 '25	Sale	23.25	22,249	517,189	85,852	Dec 03 06:14 PM
Hughes Douglas J.	Director	Dec 01 '25	Sale	23.24	15,000	348,665	120,773	Dec 03 06:14 PM
ANDREW J FROMKIN	Director	Dec 01 '25	Proposed Sale	24.15	22,249	537,313		Dec 01 04:35 PM
DOUGLAS HUGHES	Director	Dec 01 '25	Proposed Sale	24.15	15,000	362,250		Dec 01 04:34 PM
MICHAEL GEFFNER	Officer	Nov 26 '25	Proposed Sale	23.70	50,000	1,185,045		Nov 26 05:07 PM
MICHAEL GEFFNER	Officer	Nov 25 '25	Proposed Sale	23.38	103,897	2,428,804		Nov 25 07:16 PM
Gloria Melanie	Chief Operating Officer	Nov 20 '25	Sale	23.62	12,626	298,237	173,511	Nov 21 04:24 PM
Geffner Michael	Chief Medical Officer	Oct 22 '25	Sale	19.03	2,595	49,383	217,958	Oct 24 04:38 PM
Stout Jay S	Chief Technology Officer	Oct 22 '25	Sale	19.03	2,520	47,956	200,814	Oct 24 04:36 PM
Geffner Michael	Chief Medical Officer	Oct 08 '25	Sale	16.30	1,272	20,734	220,553	Oct 10 04:03 PM
Stout Jay S	Chief Technology Officer	Oct 08 '25	Sale	16.30	1,585	25,836	203,334	Oct 10 04:01 PM
Stout Jay S	Chief Technology Officer	Jul 23 '25	Sale	18.15	2,805	50,911	204,919	Jul 25 05:11 PM
Geffner Michael	Chief Medical Officer	Jul 23 '25	Sale	18.15	2,385	43,288	221,825	Jul 25 05:10 PM
Geffner Michael	Chief Medical Officer	Jul 09 '25	Sale	17.24	1,160	19,998	224,210	Jul 11 04:15 PM
Stout Jay S	Chief Technology Officer	Jul 09 '25	Sale	17.24	1,519	26,188	207,724	Jul 11 04:13 PM
WILLIAM MACIAS	Officer	Jun 25 '25	Proposed Sale	15.83	30,000	474,861		Jun 25 04:02 PM
WILLIAM MACIAS	Officer	Jun 13 '25	Proposed Sale	15.57	50,000	778,490		Jun 13 05:34 PM
WILLIAM MACIAS	Officer	Jun 03 '25	Proposed Sale	15.61	80,000	1,248,616		Jun 03 05:42 PM
GEORGE V MIGAUSKY	Former Director	May 21 '25	Proposed Sale	14.58	21,812	318,047		May 21 04:24 PM
GEORGE V MIGAUSKY	Former Director	May 19 '25	Proposed Sale	14.58	28,188	410,908		May 19 04:40 PM
Stout Jay S	Chief Technology Officer	Apr 23 '25	Sale	14.79	1,925	28,471	209,243	Apr 25 04:17 PM
Geffner Michael	Chief Medical Officer	Apr 23 '25	Sale	14.79	2,349	34,742	225,370	Apr 25 04:15 PM
Barnett Eva Renee	Chief Financial Officer	Apr 16 '25	Sale	14.89	2,993	44,566	396,774	Apr 17 04:08 PM
Salzmann Peter	Chief Executive Officer	Apr 16 '25	Sale	14.89	8,321	123,900	1,178,191	Apr 17 04:07 PM
Salzmann Peter	Chief Executive Officer	Apr 09 '25	Sale	12.99	28,094	364,941	1,186,512	Apr 11 04:05 PM

Open in Screener

ROIV

Roivant Sciences Ltd

Apr 02 • 04:00PM ET

28.33

+0.49 1.76 %

Healthcare • Biotechnology • United Kingdom • NASD

ROIV Roivant Sciences Ltd daily Stock Chart

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: IJH VTI VB VBK VXF XMMO IBB MDY XBI SPMD

Index	-	P/E	-	EPS (ttm)	-1.17	Insider Own	31.76%	Shs Outstand	709.69M	Perf Week	3.58%
Market Cap	20.28B	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-10.79%	Shs Float	488.39M	Perf Month	-4.03%
Enterprise Value	16.56B	PEG	-	EPS next Q	-0.29	Inst Own	68.28%	Short Float	4.79%	Perf Quarter	30.55%
Income	-809.24M	P/S	1523.35	EPS this Y	-366.11%	Inst Trans	2.15%	Short Ratio	3.66	Perf Half Y	79.87%
Sales	13.31M	P/B	4.71	EPS next Y	-5.86%	ROA	-14.69%	Short Interest	23.39M	Perf YTD	30.55%
Book/sh	6.02	P/C	4.47	EPS next 5Y	-	ROE	-17.11%	52W High	30.33 -6.59%	Perf Year	181.05%
Cash/sh	6.33	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-18.53%	52W Low	8.73 224.51%	Perf 3Y	283.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	60.46%	Volatility	4.51% 3.66%	Perf 5Y	189.67%
Dividend TTM	-	EV/Sales	1243.96	EPS Y/Y TTM	-751.06%	Oper. Margin	-9130.53%	ATR (14)	1.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.66	Sales Y/Y TTM	-86.36%	Profit Margin	-6079.94%	RSI (14)	56.53	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	30.66	EPS Q/Q	-262.80%	SMA20	1.11%	Beta	1.24	Target Price	34.27
Payout	-	Debt/Eq	0.03	Sales Q/Q	-77.83%	SMA50	6.44%	Rel Volume	0.78	Prev Close	27.84
Employees	750	LT Debt/Eq	0.02	Earnings	Feb 06 BMO	SMA200	49.86%	Avg Volume	6.39M	Price	28.33
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	43.41% -60.65%	Trades		Volume	5,013,342	Change	1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-26	Initiated	Bernstein	Outperform	$35
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-02-26 05:00AM	Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) (GlobeNewswire)
05:00AM	Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) (GlobeNewswire)
Mar-28-26 03:00PM	New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis (GlobeNewswire)
Mar-04-26 04:04PM	Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily) +6.00%
02:35PM	Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. (Barrons.com)
09:55AM	Loading…
09:55AM	MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS (Zacks)
09:15AM	Stocks to Watch Wednesday: Coinbase, CrowdStrike, Gitlab, Moderna (The Wall Street Journal)
09:01AM	Moderna Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily)
08:40AM	Moderna and Ross Stores Lead Stock Gainers on Wednesday (24/7 Wall St.)
08:14AM	Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars (Benzinga)
Mar-03-26 04:15PM	Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna (GlobeNewswire)
07:00AM	Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis (GlobeNewswire)
Feb-14-26 01:29AM	Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data (Insider Monkey)
Feb-10-26 06:41AM	TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why (Insider Monkey)
Feb-08-26 08:39AM	Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
06:38AM	Loading…
Feb-07-26 06:38AM	Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress (Insider Monkey)
Feb-06-26 02:05PM	Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters (Benzinga) +22.14%
02:00PM	Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga)
10:10AM	Roivant Sciences Q3 Earnings Call Highlights (MarketBeat)
10:03AM	Roivant Sciences Catapults On A 'Dream Scenario' For Its Blockbuster Hopeful (Investor's Business Daily)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
07:00AM	Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) (GlobeNewswire)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-23-26 04:15PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-20-26 10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-02-26 10:50AM	Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline (Insider Monkey)
Dec-22-25 08:10AM	Insider Action: Multimillion-dollar sell-offs across major U.S. companies (CNBC TV)
Dec-11-25 07:30AM	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day (GlobeNewswire) +5.43%
02:00AM	Loading…
Dec-10-25 02:00AM	A Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:00AM	A former Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire) -5.31%
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fitzgerald Meghan	Director	Mar 26 '26	Option Exercise	8.80	70,000	616,000	112,963	Mar 30 09:01 PM
Fitzgerald Meghan	Director	Mar 26 '26	Sale	27.45	70,000	1,921,500	42,963	Mar 30 09:01 PM
MEGHAN FITZGERALD	Director	Mar 26 '26	Proposed Sale	27.45	70,000	1,921,458		Mar 26 04:14 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Option Exercise	3.85	200,000	770,000	1,847,546	Mar 19 06:36 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Sale	28.24	200,000	5,648,000	1,647,546	Mar 19 06:36 PM
Epperly Melissa B,	Director	Mar 16 '26	Sale	28.68	41,861	1,200,573	15,804	Mar 18 06:23 PM
Venker Eric	Officer	Mar 17 '26	Proposed Sale	28.24	200,000	5,648,836		Mar 17 04:17 PM
MELISSA B EPPERLY	Director	Mar 16 '26	Proposed Sale	28.68	41,861	1,200,498		Mar 16 04:04 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Option Exercise	3.85	1,400,000	5,390,000	15,136,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Option Exercise	3.85	1,012,610	3,898,548	14,749,157	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Option Exercise	3.85	587,390	2,261,452	14,323,937	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Sale	27.42	1,400,000	38,388,000	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Sale	27.15	1,012,610	27,492,362	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Sale	27.51	587,390	16,159,099	13,736,547	Feb 23 08:40 PM
FRANK TORTI	Officer	Feb 20 '26	Proposed Sale	27.52	1,600,000	44,032,000		Feb 20 04:29 PM
FRANK TORTI	Officer	Feb 19 '26	Proposed Sale	27.48	1,400,000	38,472,000		Feb 19 04:24 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Feb 18 05:57 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Sale	26.49	200,000	5,298,000	1,654,597	Feb 18 05:57 PM
MANCHESTER KEITH S	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:02 PM
Gold Daniel Allen	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:00 PM
QVT Financial LP	Director by Deputization	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 08:45 PM
Venker Eric	Officer	Feb 13 '26	Proposed Sale	26.49	200,000	5,298,373		Feb 13 04:21 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Option Exercise	12.68	651,558	8,261,755	19,488,105	Feb 11 05:53 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Sale	26.47	339,441	8,985,003	19,148,664	Feb 11 05:53 PM
Sukhatme Mayukh	Officer	Feb 09 '26	Proposed Sale	26.47	339,441	8,985,276		Feb 09 04:13 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Jan 14 09:00 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Sale	21.92	200,000	4,384,000	1,654,597	Jan 14 09:00 PM
Venker Eric	Officer	Jan 12 '26	Proposed Sale	21.92	200,000	4,383,694		Jan 12 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Option Exercise	12.68	2,449,877	31,064,440	21,286,424	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Option Exercise	12.68	748,358	9,489,179	19,584,905	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Sale	21.71	1,018,995	22,122,381	20,267,429	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Sale	21.74	311,873	6,780,119	19,273,032	Dec 31 09:00 PM
Sukhatme Mayukh	Officer	Dec 31 '25	Proposed Sale	21.71	1,018,995	22,119,828		Dec 31 04:30 PM
Pulik Richard	CFO	Dec 23 '25	Option Exercise	3.85	260,000	1,001,000	646,144	Dec 29 09:00 PM
Pulik Richard	CFO	Dec 23 '25	Sale	22.43	406,731	9,122,307	239,413	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Option Exercise	3.85	313,841	1,208,288	1,811,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Option Exercise	3.85	117,848	453,715	1,729,597	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Sale	22.45	200,000	4,490,000	1,611,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Sale	22.53	75,000	1,689,750	1,654,597	Dec 29 09:00 PM
Sukhatme Mayukh	Officer	Dec 29 '25	Proposed Sale	21.74	311,873	6,781,263		Dec 29 04:31 PM
ERIC VENKER	Officer	Dec 24 '25	Proposed Sale	22.53	75,000	1,689,562		Dec 29 09:36 AM
FRANK M TORTI	Officer	Dec 24 '25	Proposed Sale	22.47	64,891	1,458,373		Dec 29 09:05 AM
RICHARD PULIK	Officer	Dec 23 '25	Proposed Sale	22.45	260,000	5,835,726		Dec 23 04:19 PM
RICHARD PULIK TRUST	Officer	Dec 23 '25	Proposed Sale	22.39	146,731	3,285,755		Dec 23 04:07 PM
ERIC VENKER	Officer	Dec 23 '25	Proposed Sale	22.45	200,000	4,490,540		Dec 23 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Option Exercise	12.68	59,513	754,625	18,896,060	Dec 19 09:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Sale	23.09	26,831	619,528	18,869,229	Dec 19 09:04 PM
Gold Daniel Allen	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:54 PM
Gold Daniel Allen	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:54 PM
MANCHESTER KEITH S	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:52 PM
MANCHESTER KEITH S	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:52 PM
QVT Financial LP	Director by Deputization	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:41 PM
QVT Financial LP	Director by Deputization	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:41 PM
Gline Matthew	CEO	Dec 15 '25	Option Exercise	12.16	3,870,659	47,062,049	19,559,933	Dec 17 09:00 PM
Gline Matthew	CEO	Dec 15 '25	Sale	21.68	1,740,000	37,723,200	17,290,820	Dec 17 09:00 PM
Sukhatme Mayukh	Officer	Dec 17 '25	Proposed Sale	23.09	26,831	619,488		Dec 17 05:09 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Option Exercise	12.68	4,672,724	59,250,140	38,326,479	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Option Exercise	12.68	1,869,691	23,707,682	35,523,447	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Option Exercise	12.68	832,453	10,555,504	34,486,208	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Sale	21.96	1,975,858	43,389,842	36,350,621	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Sale	21.64	774,142	16,752,433	34,749,305	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Sale	22.05	353,745	7,800,077	34,132,463	Dec 15 09:34 PM
Gline Matthew	Officer	Dec 15 '25	Proposed Sale	21.68	1,740,000	37,723,200		Dec 15 04:36 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Option Exercise	3.85	200,000	770,000	1,697,908	Dec 11 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Sale	20.85	200,000	4,170,000	1,497,908	Dec 11 09:00 PM
Venker Eric	Officer	Dec 09 '25	Proposed Sale	20.85	200,000	4,169,131		Dec 09 04:49 PM
MANCHESTER KEITH S	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:24 PM
Gold Daniel Allen	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:22 PM
QVT Financial LP	Director by Deputization	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:15 PM
Ramaswamy Vivek	10% Owner	Nov 14 '25	Sale	20.33	1,027,670	20,892,531	34,193,406	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 17 '25	Sale	20.51	539,650	11,068,222	33,653,756	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 13 '25	Sale	20.81	287,283	5,978,359	35,221,076	Nov 17 05:52 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Option Exercise	3.85	200,000	770,000	1,704,959	Nov 07 09:00 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Sale	20.22	200,000	4,044,000	1,504,959	Nov 07 09:00 PM
Venker Eric	Officer	Nov 07 '25	Proposed Sale	20.22	200,000	4,043,960		Nov 07 03:15 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Option Exercise	15.85	414,683	6,572,726	1,919,642	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Option Exercise	15.85	318,282	5,044,770	1,823,241	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Option Exercise	15.85	118,418	1,876,925	1,623,377	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Sale	16.93	414,683	7,020,583	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Sale	17.05	318,282	5,426,708	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Sale	17.06	118,418	2,020,211	1,504,959	Oct 17 09:00 PM
Venker Eric	Officer	Oct 17 '25	Proposed Sale	17.06	118,418	2,020,171		Oct 17 04:01 PM
Venker Eric	Officer	Oct 16 '25	Proposed Sale	17.05	318,282	5,425,645		Oct 16 04:37 PM
Venker Eric	Officer	Oct 15 '25	Proposed Sale	16.93	414,683	7,021,429		Oct 15 04:23 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Option Exercise	15.85	104,940	1,663,299	1,609,899	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Option Exercise	15.85	20,727	328,523	1,525,686	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Sale	16.30	104,940	1,710,522	1,504,959	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Sale	16.25	20,727	336,814	1,504,959	Oct 14 09:00 PM
Venker Eric	Officer	Oct 13 '25	Proposed Sale	16.25	20,727	336,877		Oct 14 08:51 AM
Venker Eric	Officer	Oct 09 '25	Proposed Sale	16.30	104,940	1,710,040		Oct 09 04:12 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Option Exercise	7.21	355,161	2,559,093	1,860,120	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Option Exercise	13.29	171,396	2,277,775	1,676,355	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Option Exercise	8.07	138,602	1,119,164	1,643,561	Oct 08 09:00 PM

IMVT

Immunovant Inc

ROIV

Roivant Sciences Ltd

Upgrade your Finviz experience